ACE-031 vs RAD-140 (Testolone)
A side-by-side research comparison of ACE-031 and RAD-140 (Testolone) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ACE-031 | RAD-140 (Testolone) |
|---|---|---|
| Full name | ACE-031 (Soluble ActRIIB-Fc Fusion) | Testolone (RAD-140) |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational | Investigational (not approved; banned in sport) |
| Mechanism | Decoy receptor sequestering TGF-B ligands (myostatin, activin, GDF-11) in bloodstream, preventing cell-surface ActRIIB binding and removing multiple anabolic brakes. | Acts as a strong, tissue-selective androgen receptor agonist in muscle and bone, driving anabolic signaling with a higher anabolic-to-androgenic ratio than testosterone in preclinical models. |
| Molecular weight | ~90,000 Da | 393.83 Da |
| Half-life | 10-14 days | ~16-20 hours |
| Bioavailability | High (SubQ) | Oral |
| Typical dose | 0.3-3 mg/kg | Commonly cited 5-15 mg/day (research) |
| Frequency | Every 2-4 weeks | Once daily |
| Route | Subcutaneous | Oral |
ACE-031 reported benefits
- Multi-ligand pathway inhibition
- Lean mass increase
- Bone density increase
- Infrequent dosing
- Functional strength improvement
RAD-140 (Testolone) reported benefits
- Strong lean muscle gains (research)
- Increased strength
- Studied originally for muscle wasting and breast cancer
- Bone-supportive signaling
Related comparisons
Research and educational reference only. Not medical advice.